Interim report January-June 2022: ACCELERATING GROWTH AND PROFITABILITY

SECOND QUARTER 2022 (APR – JUN)

Net sales amounted to SEK 188.2 million (36.6), corresponding to an increase of 415 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 46 percent.

Operating profit amounted to SEK 38.6 million (2.2).

Net profit amounted to SEK 26.5 million (3.5), corresponding to earnings per share of SEK 0.52 (0.09).

Cash flow from operating activities amounted to an inflow of SEK 30.4 million (9.4). As of June 30, 2022, cash and cash equivalents amounted to SEK 362.3 million (267.3).

At the end of May, Surgical Science announced that its US operations had secured an order valued at USD 6.7 million (equivalent to about SEK 65.9 million) from a major US hospital chain. About USD 2.1 million of this order was recognized as revenue in the second quarter.

FIRST HALF OF 2022 (JAN–JUN)

Net sales amounted to SEK 347.4 million (73.8), corresponding to an increase of 371 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 40 percent.

Operating profit amounted to SEK 58.6 million (4.5).

Net profit amounted to SEK 43.0 million (5.0), corresponding to earnings per share of SEK 0.85 (0.13).

Cash flow from operating activities amounted to an inflow of SEK 41.5 million (0.5).

Gothenburg, Sweden, August 25, 2022
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the clinical environment. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 230 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Stockholm, Sweden, as well as in Tel Aviv, Israel and Seattle, US. Through sales offices in the US, France and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Phone: +46 8-463 83 00; E-mail: certifiedadviser@penser.se).

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-08-25 07:30 CEST.

Attachments

220825 Q22022 ENG

220825 Q22022 ENG